Home PipelineMGD019 (PD-1 × CTLA-4)

Background

MGD019 is an investigational, bispecific DART® molecule that was designed to enhance CTLA-4 blockade on dual-expressing, tumor-infiltrating lymphocytes compared to a PD-1/CTLA-4 monoclonal antibody (mAb) combination therapy, while maintaining maximal PD-1 blockade on all PD-1-expressing cells.

Clinical Development

Based upon the establishment of a recommended Phase 2 dose from a dose escalation study, MGD019 is initially being evaluated in a dose expansion study in microsatellite-stable colorectal cancer and non-small cell lung cancer.

Our Rights

MacroGenics retains global rights to MGD019.

Clinical Trials

Presentations & Publications

Relevant Publications and Presentations can be found at https://www.macrogenics.com/publications/.

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close